Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

1 treatments under study, led by Vlx1005

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05785819Phase 2Terminated

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

NCT01178333CompletedPrimary

Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study

Showing all 2 trials

Research Network

Common Treatments

  • Vlx10051

Active Sponsors

  • Veralox Therapeutics1
  • National Heart, Lung, and Blood Institute (NHLBI)1
  • Carelon Research1

Top Investigators

Related Conditions

  • Thrombocytopenia Immune1

Activity Timeline